His­to­gen files for bank­rupt­cy; Barinthus Bio shares Ph1b/2 da­ta for HPV treat­ment

Plus, news about TScan Ther­a­peu­tics:

His­to­gen files for Chap­ter 11 bank­rupt­cy: The biotech, which stopped work in Sep­tem­ber, filed a pe­ti­tion with the US Bank­rupt­cy Court for the South­ern Dis­trict of Cal­i­for­nia. Its next steps in­clude con­firm­ing a plan of liq­ui­da­tion to dis­trib­ute val­ue to stake­hold­ers. — Ay­isha Shar­ma 

Barinthus Bio touts Ph1b/2 HPV da­ta: The com­pa­ny’s im­munother­a­py can­di­date, VTP-200, met the pri­ma­ry safe­ty end­point in a tri­al of 108 women with high-risk HPV-as­so­ci­at­ed low-grade cer­vi­cal le­sions. The group with the high­est treat­ment dose achieved a 60% high-risk HPV clear­ance rate at 12 months ver­sus a 33% clear­ance rate for place­bo. — Ay­isha Shar­ma 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER